SEC Form 3 filed by Regencell Bioscience Holdings Limited
$RGC
Medicinal Chemicals and Botanical Products
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)
3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)
3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
20-F - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
- The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD ("SKATBT-A3"), which measures the effectiveness of the treatment on the patient's overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. - The first efficacy trial using personalized TCM formulae have shown a mean percentage improvement of 30% in ADHD symptoms and a mean percentage improvement of 37% in ASD symptoms, based on the scoring systems under the Vanderbilt ADHD Diagnostic Parent Rating Scale ("VADRS") and the Autism Treatment Evaluation Checklist ("ATEC"), respectively, after 3 months of treatment. - The ongoin
Regencell Bioscience Holdings Limited (NASDAQ:RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patients) 90.2 83.8 87.5 Testing negative in 6 days (% of patients) 23.5 43.5 29.7 Recovery period for patients who took RGC-COV19TM within 3 days of sy
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman and CEO, made purchases of ordinary shares in Regencell ("Ordinary Shares") totaling $5.03 million. Based on his Schedule 13D filings with the U.S. Securities and Exchange Commission (the "SEC") between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of his personal funds to
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan